10h
GlobalData on MSNNovo Nordisk’s haemophilia A drug stops bleeds in 74% of childrenNovo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025 — This ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Danish Ambassador to Thailand Danny Annan praised Novo Nordisk yesterday for its commitment to healthcare, innovation, and fostering stronger Thai-Danish relations as the two countries look to ...
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...
14h
Zacks.com on MSNPharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings UpdateThis week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans for regulatory filing this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results